ArticleMolecular cell2022
Structural basis of SARM1 activation, substrate recognition, and inhibition by small molecules.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
14.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 130 citations in OpenAlex.
- Direct activation of SARM1 by dsDNA is not supported by biochemical and cellular evidence.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Preclinical Pharmacokinetic and Pharmacological Profiling of B339, a Novel SARM1 Inhibitor for the Treatment of Vincristine-induced Peripheral Neuropathy.Pharmaceutical research · 2026Article
- Preclinical Pharmacokinetic and Pharmacological Profiling of B339, a Novel SARM1 Inhibitor for the Treatment of Vincristine-induced Peripheral Neuropathy.Pharmaceutical research · 2026Article
- Structural mechanisms for ATP-mediated inhibition of human NLRP6 inflammasome.Nature structural & molecular biology · 2026Article
- Article
- Review
- Peripheral Neuropathy in Metabolic Stress.International journal of molecular sciences · 2026Review
- Review
- Boldine inhibits SARM1 NADase Activity and Preserves Axonal Integrity After Nerve Injury.bioRxiv : the preprint server for biology · 2026Article
- Raw defines a TIR-fold cADPR hydrolase cooperating with dSarm in development and axon degeneration.Cell communication and signaling : CCS · 2026Article
- Targeting the SARM1-cADPR-CaArthritis research & therapy · 2026Article
- The rise and fall of SARM1 base-exchange inhibitors.Communications chemistry · 2026Article
- Chemical inactivation of a bacterial immune system de-domesticates a temperate phage and promotes its spread.bioRxiv : the preprint server for biology · 2026Article
- TIR-like NADases act in bacterial immunity and the RNA vault.bioRxiv : the preprint server for biology · 2026Article
- Structural Mechanism of Receptor-Triggered MyD88 Oligomeric Assembly in Innate Immune Signaling.Nature communications · 2026Article
- SARM1 activation promotes axonal degeneration via a two-step phase transition.Nature chemical biology · 2026Article
- Chemical inhibition of a bacterial immune system.Cell host & microbe · 2026Article
- Neuronal guidance signaling in neurodegenerative diseases: Key regulators that function at neuron-glia and neuroimmune interfaces.Neural regeneration research · 2026Article
- Molecular mechanisms of plant NLR activation and signalling.The Plant journal : for cell and molecular biology · 2026Review
- Caspase-3 cleaves and activates the NADase SARM1 to promote apoptosis, linking two cell death mechanisms.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 6 institutions in 4 countries.
Yun ShiInstitute for Glycomics, Griffith University, Southport, QLD 4222, Australia.
Philip S KerryEvotec (UK) Ltd., 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, UK.
Jeffrey D NansonSchool of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, QLD 4072, Australia.
Todd BosanacDisarm Therapeutics, a wholly-owned subsidiary of Eli Lilly & Co., Cambridge, MA, USA.
Yo SasakiNeedleman Center for Neurometabolism and Axonal Therapeutics and Department of Genetics, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA.
Raul KraussDisarm Therapeutics, a wholly-owned subsidiary of Eli Lilly & Co., Cambridge, MA, USA.
Forhad K SaikotSchool of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, QLD 4072, Australia.
Sarah E AdamsEvotec (UK) Ltd., 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, UK.
Tamim MosaiabInstitute for Glycomics, Griffith University, Southport, QLD 4222, Australia.
Veronika MasicInstitute for Glycomics, Griffith University, Southport, QLD 4222, Australia.
Xianrong MaoNeedleman Center for Neurometabolism and Axonal Therapeutics and Department of Genetics, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA.
Faith RoseInstitute for Glycomics, Griffith University, Southport, QLD 4222, Australia.
Eduardo VasquezInstitute for Glycomics, Griffith University, Southport, QLD 4222, Australia.
Marieke FurrerEvotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany.
Katie CunneaEvotec (UK) Ltd., 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, UK.
Andrew BrearleyEvotec (UK) Ltd., 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, UK.
Weixi GuSchool of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, QLD 4072, Australia.
Zhenyao LuoSchool of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, QLD 4072, Australia.
Lou BrillaultCentre for Microscopy and Microanalysis, The University of Queensland, Brisbane, Australia.
Michael J LandsbergSchool of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, QLD 4072, Australia.
Aaron DiAntonioNeedleman Center for Neurometabolism and Axonal Therapeutics and Department of Developmental Biology, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA.
Bostjan KobeSchool of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, QLD 4072, Australia.
Jeffrey MilbrandtNeedleman Center for Neurometabolism and Axonal Therapeutics and Department of Genetics, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA.
Robert O HughesDisarm Therapeutics, a wholly-owned subsidiary of Eli Lilly & Co., Cambridge, MA, USA. Electronic address: rhughes@disarmtx.com.
Thomas VeInstitute for Glycomics, Griffith University, Southport, QLD 4222, Australia. Electronic address: t.ve@griffith.edu.au.
The University of Queensland · AUGriffith University · AUEvotec (United Kingdom) · GBCenter for Neuro-Oncology · USEli Lilly (United States) · USEvotec (Germany) · DE
Funding
DISSECTION OF SARM1-INDUCED AXON DEGENERATION AND CELL DEATHR01NS087632 · NINDS · WASHINGTON UNIVERSITY · PI Aaron Diantonio, JEFFREY D MILBRANDT · 2014 to 2026
$6.4MSARM1 functional polymorphisms and their contribution to ALS riskR01NS119812 · NINDS · WASHINGTON UNIVERSITY · PI BLOOM, ADAM JOSEPH, DIANTONIO, AARON · 2021 to 2025
$2.9MMedical Research Council MC_PC_17136NINDS NIH HHS R01 NS087632
Abstract
The NADase SARM1 (sterile alpha and TIR motif containing 1) is a key executioner of axon degeneration and a therapeutic target for several neurodegenerative conditions. We show that a potent SARM1 inhibitor undergoes base exchange with the nicotinamide moiety of nicotinamide adenine dinucleotide (NAD
Indexed as
Armadillo Domain ProteinsNADCytoskeletal ProteinsNAD+ NucleosidaseProtein DomainsArmadillo Domain ProteinsCytoskeletal ProteinsNADNAD+ Nucleosidaseallosteric activatorARM domainbase exchangecryo-EMNADaseorthosteric inhibitorTIR domainX-ray crystallography
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.